Arrowstreet Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15.7M | Buy |
125,162
+58,562
| +88% | +$7.36M | 0.01% | 765 |
|
|
2025
Q1 | $7.37M | Buy |
+66,600
| New | +$7.37M | 0.01% | 892 |
|
|
2024
Q4 | – | Sell |
-8,651
| Closed | -$997K | – | 1892 |
|
|
2024
Q3 | $997K | Buy |
8,651
+5,169
| +148% | +$596K | ﹤0.01% | 1388 |
|
|
2024
Q2 | $479K | Sell |
3,482
-27,281
| -89% | -$3.75M | ﹤0.01% | 1339 |
|
|
2024
Q1 | $4.24M | Buy |
+30,763
| New | +$4.24M | ﹤0.01% | 938 |
|
|
2023
Q3 | – | Sell |
-71,770
| Closed | -$6.77M | – | 1361 |
|
|
2023
Q2 | $6.77M | Sell |
71,770
-4,842
| -6% | -$457K | 0.01% | 578 |
|
|
2023
Q1 | $7.76M | Buy |
76,612
+12,386
| +19% | +$1.25M | 0.01% | 594 |
|
|
2022
Q4 | $7.67M | Sell |
64,226
-143,124
| -69% | -$17.1M | 0.01% | 583 |
|
|
2022
Q3 | $22M | Buy |
207,350
+100,361
| +94% | +$10.7M | 0.03% | 357 |
|
|
2022
Q2 | $10.4M | Buy |
106,989
+10,706
| +11% | +$1.04M | 0.01% | 488 |
|
|
2022
Q1 | $9.03M | Sell |
96,283
-16,099
| -14% | -$1.51M | 0.01% | 532 |
|
|
2021
Q4 | $9.57M | Buy |
+112,382
| New | +$9.57M | 0.01% | 664 |
|
|
2020
Q4 | – | Sell |
-12,900
| Closed | -$1.24M | – | 2452 |
|
|
2020
Q3 | $1.24M | Buy |
+12,900
| New | +$1.24M | ﹤0.01% | 1753 |
|
|
2018
Q4 | – | Sell |
-18,400
| Closed | -$2.26M | – | 1448 |
|
|
2018
Q3 | $2.26M | Buy |
+18,400
| New | +$2.26M | 0.01% | 664 |
|
|
2018
Q2 | – | Sell |
-18,600
| Closed | -$1.54M | – | 1233 |
|
|
2018
Q1 | $1.54M | Buy |
+18,600
| New | +$1.54M | ﹤0.01% | 789 |
|
|
2014
Q1 | – | Sell |
-60,409
| Closed | -$564K | – | 1263 |
|
|
2013
Q4 | $564K | Sell |
60,409
-42,881
| -42% | -$400K | ﹤0.01% | 948 |
|
|
2013
Q3 | $1.17M | Buy |
+103,290
| New | +$1.17M | 0.01% | 633 |
|